Table 4.

Stratification analysis of TUG1 polymorphisms and clinical characteristics of IS

Variables	rs2240183			rs5749201			rs5753409			rs7284767			rs8139350
	TT	CT/CC	P	TT	AT/AA	P	GG	AG/AA	P	AA	AG/GG	P	CC	CG/GG	P
TC, mmol/L	4.80 ± 1.05	4.78 ± 1.00	0.78	4.88 ± 0.92	4.70 ± 1.08	0.03	4.81 ± 1.03	4.69 ± 0.97	0.22	4.79 ± 1.01	4.77 ± 1.03	0.82	4.78 ± 1.01	4.80 ± 1.03	0.84
TG, mmol/L	1.94 ± 1.39	1.86 ± 1.44	0.54	1.86 ± 1.26	1.89 ± 1.55	0.81	1.85 ± 1.28	1.97 ± 1.83	0.41	1.94 ± 1.62	1.79 ± 1.07	0.22	1.89 ± 1.48	1.83 ± 1.16	0.71
HDL‐C, mmol/L	1.27 ± 0.41	1.31 ± 0.40	0.31	1.35 ± 0.42	1.25 ± 0.39	0.003	1.30 ± 0.41	1.27 ± 0.39	0.48	1.29 ± 0.40	1.30 ± 0.41	0.70	1.28 ± 0.40	1.34 ± 0.44	0.18
LDL‐C, mmol/L	2.91 ± 0.97	2.79 ± 0.99	0.17	2.80 ± 1.04	2.86 ± 0.94	0.45	2.84 ± 0.98	2.80 ± 0.99	0.66	2.82 ± 1.02	2.85 ± 0.93	0.76	2.84 ± 0.97	2.79 ± 1.04	0.66
VLDL‐C,mmol/L	0.90 ± 0.78	0.80 ± 0.59	0.11	0.82 ± 0.65	0.85 ± 0.67	0.69	0.83 ± 0.62	0.84 ± 0.79	0.94	0.87 ± 0.80	0.79 ± 0.37	0.14	0.85 ± 0.70	0.76 ± 0.43	0.23
Apo‐A1, g/L	1.22 ± 0.24	1.23 ± 0.27	0.73	1.26 ± 0.26	1.20 ± 0.26	0.007	1.23 ± 0.26	1.21 ± 0.24	0.44	1.24 ± 0.26	1.21 ± 0.27	0.23	1.22 ± 0.26	1.25 ± 0.25	0.35
Apo‐B, g/L	1.00 ± 0.30	1.00 ± 0.30	0.97	1.02 ± 0.31	0.99 ± 0.29	0.20	1.00 ± 0.30	1.00 ± 0.31	0.86	1.01 ± 0.31	1.00 ± 0.29	0.83	1.00 ± 0.30	1.01 ± 0.28	0.80
Hcy, μmol/L	14.08 ± 5.04	14.28 ± 6.16	0.70	14.58 ± 6.14	13.91 ± 5.53	0.17	14.33 ± 6.14	13.81 ± 4.55	0.38	14.08 ± 5.84	14.41 ± 5.79	0.50	14.27 ± 6.03	13.96 ± 4.72	0.63
NEFA, mmol/L	0.57 ± 0.29	0.54 ± 0.28	0.14	0.55 ± 0.28	0.55 ± 0.29	0.90	0.55 ± 0.29	0.53 ± 0.28	0.40	0.54 ± 0.28	0.55 ± 0.28	0.61	0.55 ± 0.27	0.52 ± 0.32	0.31

Apo‐A1, apolipoprotein A1; Apo‐B, apolipoprotein B; Hcy, homocysteic acid; HDL‐C, high‐density lipoprotein cholesterol; IS, ischaemic stroke; LDL‐C, low‐density lipoprotein cholesterol; NEFA, non‐esterified fatty acid; TC, total cholesterol; TG, triglyceride; TUG1, taurine‐upregulated gene 1; VLDL‐C, very low‐density lipoprotein cholesterol.